b>j)΄!Pԫ&;"kB޶}pSVT(wę!j x;-m@JnQ+պכ7MajfJͱ4jѲ撆RxZMz7vIW/dٞТזcZM~ji ߒsQzԠDW3Den"M+/B:-uIJ7j委9p='mANޭ=/B:-n&nUfqxZM~c Ϲ+,&ᾺܢF[(1*" ϒ"Jԧ<;b" "jܢF[x ,!q қ*]/؝27SMcs"ޭDQ/应ܢF_! :s" 7`F+SVTn"IJnQ/应B 4 wD"IJ׭-`S9DrjiEJ߅gJ应矁[xZM~n"IB؃!'Тѕ+(mIKʭ/|ϐܢF[xZMzG %嬩/c[[ March 13, 2025 – Visionary Ventures
Skip to content
Visionary Ventures
Life sciences venture capital fund investing in ophthalmology and medical aesthetics.
Visionary VenturesVisionary Ventures
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN
Fund Menu
Search
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN

Daily Archives: March 13, 2025

Sydnexis Announces FDA Acceptance of NDA for SYD-101 for the Treatment of Progression of Pediatric Myopia

News, SydnexisBy Garrett HamontreeMarch 13, 2025

Sydnexis announced that the FDA has accepted its new drug application (NDA) for SYD-101, which if approved would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025.

  • Home
  • Ophthalmology
  • Team
    • Investment Committee
    • Visionary KOLs
    • Fund Management
  • Portfolio
  • News
  • Contact
  • Investor Portal
Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.

Go to Top